Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
YTH N6-methyladenosine RNA binding protein 2 (YTHDF2)
- Target
- YTHDF2
- Molecular classification
- RNA binding protein, m6A reader, Post-transcriptional regulator
01
Overview
YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) is an RNA binding protein that recognizes and binds N6-methyladenosine (m6A) modifications in RNA. It acts as a key "reader" of the m6A epitranscriptomic mark, primarily in the cytoplasm. Upon binding m6A-modified mRNAs, YTHDF2 recruits the CCR4—NOT deadenylase complex to promote rapid degradation of these transcripts, thus regulating mRNA stability and turnover. This post-transcriptional control impacts cell proliferation, apoptosis, and other essential biological processes. Dysregulation of YTHDF2 is implicated in cancer progression (notably bladder cancer) and may serve as a prognostic biomarker.
- Other names
- YTHDF2HGRG8NY-REN-2CAHLDF2
02
Mechanism of action
Compounds or molecules targeting YTHDF2 would be expected to modulate mRNA stability by altering recognition or degradation of m6A-marked mRNAs
03
Biological functions
mRNA stability regulation (promotes degradation of m6A-containing mRNAs)RNA metabolism, including pre-mRNA splicing, export, and translationRegulation of cell proliferation, apoptosis, cell cycle, viability, migration, and invasion
04
Disease associations
Cancer (notably associated with bladder cancer and other malignancies)Potential roles in polycystic ovary syndrome and mitochondrial dysfunction
05
Safety considerations
Potential for broad effects on mRNA metabolism, leading to possible off-target disturbances in cell functionModulation may impact cell proliferation and apoptosis, affecting tumorigenesis or other cellular homeostasis
06
Biomarkers
Proposed as a diagnostic/prognostic biomarker in cancer, particularly bladder cancer
Beyond the preview
Go deeper on YTH N6-methyladenosine RNA binding protein 2 (YTHDF2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YTH N6-methyladenosine RNA binding protein 2 (YTHDF2).